Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-019-01816-4
Abstract: Background Dotinurad is a novel, selective urate reabsorption inhibitor, which reduces serum uric acid levels by inhibiting the urate transporter 1 (URAT1). We compared the pharmacokinetics (PK), pharmacodynamics (PD), and safety of dotinurad in subjects… read more here.
Keywords: hepatic impairment; group; study; novel selective ... See more keywords
A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad
Sign Up to like & getrecommendations! Published in 2023 at "Cardiology Research"
DOI: 10.14740/cr1496
Abstract: We previously reported that the switching from fenofibrate to the selective peroxisome proliferator-activated receptor (PPAR) α modulator, pemafibrate, increased serum uric acid (UA) levels and reduced estimated glomerular filtration rate (eGFR) in patients with dyslipidemia… read more here.
Keywords: disease; kidney; abcg2; dotinurad ... See more keywords
Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1042061
Abstract: Background Dotinurad is a novel uricosuric drug in Japan with selective and potent urate transporter 1 (URAT1) inhibitory activity. This study aims to evaluate the efficacy and safety of dotinurad in hyperuricemic patients with type… read more here.
Keywords: type diabetic; dotinurad; kidney disease; diabetic kidney ... See more keywords